Safety, efficacy and renal effect of febuxostat in patients with moderate-to-severe kidney dysfunction (Q88106543)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24942770%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

title

Safety, efficacy and renal effect of febuxostat in patients with moderate-to-severe kidney dysfunction (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24942770%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

author name string

Yugo Shibagaki

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24942770%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

Iwao Ohno

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24942770%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

Tatsuo Hosoya

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24942770%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

Kenjiro Kimura

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24942770%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

publication date

19 June 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24942770%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

published in

Hypertension Research

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24942770%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

volume

37

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24942770%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

page(s)

919-925

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24942770%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

issue

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24942770%20AND%20SRC:MED&resulttype=core&format=json

Changes in serum uric acid have a reciprocal effect on eGFR change: a 10-year follow-up study of community-based screening in Okinawa, Japan

20 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FHR.2014.107

7 January 2021

Uric acid and chronic kidney disease: new understanding of an old problem

1 reference

https://api.crossref.org/works/10.1038%2FHR.2014.107

7 January 2021

Association of hyperuricemia with renal outcomes, cardiovascular disease, and mortality

1 reference

https://api.crossref.org/works/10.1038%2FHR.2014.107

7 January 2021

Increased uric acid promotes decline of the renal function in hypertensive patients: a 10-year observational study

1 reference

https://api.crossref.org/works/10.1038%2FHR.2014.107

7 January 2021

Prevalence of contraindications and prescription of pharmacologic therapies for gout.

1 reference

https://api.crossref.org/works/10.1038%2FHR.2014.107

7 January 2021

Challenges associated with the management of gouty arthritis in patients with chronic kidney disease: a systematic review

1 reference

https://api.crossref.org/works/10.1038%2FHR.2014.107

7 January 2021

The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial

1 reference

https://api.crossref.org/works/10.1038%2FHR.2014.107

7 January 2021

A repeated oral administration study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with impaired renal function in Japan: pharmacokinetic and pharmacodynamic study

1 reference

https://api.crossref.org/works/10.1038%2FHR.2014.107

7 January 2021

Revised equations for estimated GFR from serum creatinine in Japan

1 reference

https://api.crossref.org/works/10.1038%2FHR.2014.107

7 January 2021

Japanese guideline for the management of hyperuricemia and gout: second edition.

1 reference

https://api.crossref.org/works/10.1038%2FHR.2014.107

7 January 2021

Acute neutropenia associated with initiation of febuxostat therapy for hyperuricaemia in patients with chronic kidney disease

1 reference

https://api.crossref.org/works/10.1038%2FHR.2014.107

7 January 2021

Metabolism and excretion of [14C] febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase, in healthy male subjects.

1 reference

https://api.crossref.org/works/10.1038%2FHR.2014.107

7 January 2021

Association between adverse reactions to allopurinol and exposures to high maintenance doses: implications for management of patients using allopurinol

1 reference

https://api.crossref.org/works/10.1038%2FHR.2014.107

7 January 2021

Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial

1 reference

https://api.crossref.org/works/10.1038%2FHR.2014.107

7 January 2021

Management of asymptomatic hyperuricaemia in patients with chronic kidney disease by Japanese nephrologists: a questionnaire survey

1 reference

https://api.crossref.org/works/10.1038%2FHR.2014.107

7 January 2021

Significance of hyperuricemia on the early detection of renal failure in a cohort of screened subjects

1 reference

https://api.crossref.org/works/10.1038%2FHR.2014.107

7 January 2021

Challenges of conducting a trial of uric-acid-lowering therapy in CKD.

1 reference

https://api.crossref.org/works/10.1038%2FHR.2014.107

7 January 2021

Renal function in gout: long-term treatment effects of febuxostat

1 reference

https://api.crossref.org/works/10.1038%2FHR.2014.107

7 January 2021

Comparison of febuxostat and allopurinol for hyperuricemia in cardiac surgery patients (NU-FLASH Trial).

1 reference

https://api.crossref.org/works/10.1038%2FHR.2014.107

7 January 2021

Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial

1 reference

https://api.crossref.org/works/10.1038%2FHR.2014.107

7 January 2021

Febuxostat suppressed renal ischemia-reperfusion injury via reduced oxidative stress

1 reference

https://api.crossref.org/works/10.1038%2FHR.2014.107

7 January 2021

Use of xanthine oxidase inhibitor febuxostat inhibits renal interstitial inflammation and fibrosis in unilateral ureteral obstructive nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FHR.2014.107

7 January 2021

Uric acid and chronic kidney disease: which is chasing which?

1 reference

https://api.crossref.org/works/10.1038%2FHR.2014.107

7 January 2021

Identifiers

DOI

10.1038/HR.2014.107

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24942770%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

1 reference